VIEWPOINT MOLECULAR TARGETING, INC.
SSTR2-targeted alpha-particle radiopharmaceutical ([212Pb]VMT-α-NET) for neuroblastoma treatment
- Sector
- Biotech
- Headquarters
- Coralville, IA
- Latest Form D
- $8.8M, Dec 2020
- Total capital
- $24.7M
- Federal grants
- $13M
- 15 awards · 2015–2024
- Rank in peer group#24 of 514
- Private capital raised
- $9.4M
- 2 Form D · last Dec 2020
- 71 months since last filing
- Federal contracts
- $2.2M
- 2 awards · Health and Human S
- Rank in Biotech#132 of 4373
- Granted patents
- 0
- 7 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Antibody-based prertargeted alpha particle therapy for ovarian cancer$392K
- Federal grantHealth and Human S · Phase II · Image-guided dosimetry-based alpha particle therapy for neuroblastoma.$961K
- Federal grantHealth and Human S · Phase II · Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma$948K
- Federal grantHealth and Human S · Phase II · Image-guided dosimetry-based alpha particle therapy for neuroblastoma.$2M
- Federal grantHealth and Human S · Phase II · Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma$977K
- Federal grantHealth and Human S · Phase II · Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors.$999K
- Federal grantHealth and Human S · Phase II · GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.$1.0M
- Private capital raisedForm D · SEC · 2nd filing$8.8M
- Private capital raisedForm D · SEC · 1st filing$600K
Show 10 earlier federal awards
- Federal grantHealth and Human S · Phase II · Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors.$998K
- Federal grantHealth and Human S · Phase II · GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.$1.0M
- Federal grantHealth and Human S · Phase II · Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma$1M
- Federal grantHealth and Human S · Phase II · Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma$2M
- Federal grantHealth and Human S · Phase I · Receptor-targeted radionuclide therapy combined with immunotherapies to improve metastatic melanoma tumor response.$300K
- Federal contractHealth and Human S · Igf::ot::igf "systemic Targeted Radionuclide Therapy For Metastatic Melanoma"$1.9M
- Federal grantHealth and Human S · Phase I · Production of Image-Guided Metastatic Melanoma Therapy Radiopharmaceuticals$50K
- Federal grantHealth and Human S · Phase I · Production of Image-Guided Metastatic Melanoma Therapy Radiopharmaceuticals$299K
- Federal contractHealth and Human S · SBIR Phase I-radionuclide Therapy For Metastatic Melanoma Viewpoint Molecular Targeting, LLC:1256544 [15-068338] Igf::ot::igf$298K
- Federal grantHealth and Human S · Phase I · Image guided therapy for metastatic melanoma$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
46months
from VIEWPOINT MOLECULAR TARGETING, INC.’s first federal award to its first private round.
- First federal award · Apr 2015
- Health and Human S · $150K
- First Form D · Feb 2019
- $600K · 1st Form D
- Awards before first raise
- 5 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#24 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Frances JohnsonResearcherExecutive Officer, DirectorLinked by $3.8M in grants as PI
- Michael SchultzResearcherExecutive Officer, DirectorLinked by $2M in grants as PI
- Cameron GrayDirectorNamed in SEC Form D filings
- Curtis NelsonDirectorNamed in SEC Form D filings
- Heyward ColemanExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 7- PendingFibroblast Activation Protein Targeting PeptidesUSPTOApplication 18767232
- PendingFibroblast Activation Protein Targeting PeptidesUSPTOApplication 18537730
- PendingRemoval Of Free-unlabeled Cationic And Anionic Solution Phase Radionuclides From Radiopharmaceuticals Using Solid-phase Extraction TechniquesUSPTOApplication 18369037
Show all 7 patent records
- Fibroblast Activation Protein Targeting PeptidesJun 12, 2025 · Application 18767232Pending
- Fibroblast Activation Protein Targeting PeptidesJun 12, 2025 · Application 18537730Pending
- Removal Of Free-unlabeled Cationic And Anionic Solution Phase Radionuclides From Radiopharmaceuticals Using Solid-phase Extraction TechniquesMar 21, 2024 · Application 18369037Pending
- Systems And Methods For Generating RadionuclidesApplication 63519817Pending
- Systems And Methods For Generating RadionuclidesApplication PCTUS2023069474Pending
- Removal Of Free-unlabeled Cationic And Anionic Solution Phase Radionuclides From Radiopharmaceuticals Using Solid-phase Extraction TechniquesApplication 63407410Pending
- Systems And Methods For Generating RadionuclidesApplication 63402906Pending
Related companies, and why
- CHROMATAN INCSimilar federal contract value in Biotech · $2.3M in contracts
- WILSON WOLF MANUFACTURING CORPORATIONSimilar federal contract value in Biotech · $2.3M in contracts
- MODULATION THERAPEUTICS, INC.Similar federal contract value in Biotech · $2.3M in contracts
- Vector Biomed Inc.Similar federal contract value in Biotech · $2.2M in contracts
- MerusSimilar federal contract value in Biotech · $2.1M in contracts
- GENCIRQ, INC.Similar federal contract value in Biotech · $2M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .